Long-term follow-up of oral live attenuated human rotavirus vaccine efficacy and safety in Finnish infants previously enrolled in Rota-036

Phase 3, open-label trial of rotavirus vaccine, live, attenuated in rotaviral diarrhea (2 arms), sponsored by GSK. Primary endpoint: Occurrence of any rotavirus gastroenteritis caused by circulating wild-type rotavirus strains during the long-term follow-up study period. Started Dec 2006; status: completed.